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Context: Polycystic ovary syndrome (PCOS) is a prevalent metabolic disorder occurring in up to 10%
of women of reproductive age. PCOS is associated with insulin resistance and cardiovascular risk.
Androgen excess is a defining feature of PCOS and has been suggested as causally associated with
insulin resistance; however, mechanistic evidence linking both is lacking. We hypothesized that
adipose tissue is an important site linking androgen activation and metabolic dysfunction in PCOS.
Methods: We performed a human deep metabolic in vivo phenotyping study examining the sys-
temic and intra-adipose effects of acute and chronic androgen exposure in 10 PCOS women, in
comparison with 10 body mass index–matched healthy controls, complemented by in vitro
experiments.
Results: PCOS women had increased intra-adipose concentrations of testosterone (P = 0.0006) and
dihydrotestosterone (P = 0.01), with increased expression of the androgen-activating enzyme
aldo-ketoreductase type 1 C3 (AKR1C3) (P = 0.04) in subcutaneous adipose tissue. Adipose glycerol
levels in subcutaneous adipose tissue microdialysate supported in vivo suppression of lipolysis after
acute androgen exposure in PCOS (P = 0.04). Mirroring this, nontargeted serum metabolomics
revealed prolipogenic effects of androgens in PCOSwomen only. In vitro studies showed that insulin
increased adipose AKR1C3 expression and activity, whereas androgen exposure increased
adipocyte de novo lipid synthesis. Pharmacologic AKR1C3 inhibition in vitro decreased de novo
lipogenesis.
Conclusions: These findings define an intra-adipose mechanism of androgen activation that
contributes to adipose remodeling and a systemic lipotoxic metabolome, with intra-adipose
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androgens driving lipid accumulation and insulin resistance in PCOS. AKR1C3 represents a promising
therapeutic target in PCOS. (J Clin Endocrinol Metab 102: 3327–3339, 2017)
Polycystic ovary syndrome (PCOS) is a prevalentdisorder in women of reproductive age, and is defined
by androgen excess (AE) and anovulatory infertility (1,
2). It affects 6.1% to 19.9% of women, depending on
diagnostic criteria applied (3). In terms of clinical con-
sequences, however, PCOS is primarily a disorder with
adverse metabolic risk impact, as evidenced by a high
prevalence of insulin resistance (4), dyslipidemia (5), and
increased rates of type 2 diabetes mellitus and hyper-
tension (3, 6), over and above those observed in simple
obesity. Recent data also highlight increased rates of
cardiovascular disease (7) and nonalcoholic fatty liver
disease (8, 9) in women affected by PCOS.
AE is a defining feature of PCOS (10); however,
its origins remain insufficiently understood. Although
traditionally perceived as a disorder of purely ovarian
origin, it is now clear that there are also complex con-
tributions from the adrenal and peripheral tissues to
PCOS-related AE (11–14). The potent androgens tes-
tosterone (T) and 5a-dihydrotestosterone (DHT) can be
activated from androgen precursors in peripheral target
tissues of androgen action (12, 15). The severity of AE
and insulin resistance in PCOS is closely correlated, but
the direction of causality remains unclear. Insulin re-
sistance because of monogenic insulin receptor mutations
has been shown to be associated with a severe AE phe-
notype (16). Conversely, monogenic causes of AE are
associated with adverse metabolic consequences and can
present with a PCOS phenotype (17–19).
One of the major metabolic compartments, adipose
tissue, is capable of androgen generation, a process that
is tightly regulated by a complex network of activat-
ing and inactivating enzymes (20). The enzyme aldo-
ketoreductase type 1C3 (AKR1C3), which converts
androstenedione (A4) to the biologically active androgen
T, is abundantly expressed in adipose tissue (21), with
increased expression in subcutaneous fat from both
womenwith simple obesity (22) and PCOS (23). Previous
work has shown that AKR1C3 is the only enzyme
expressed in adipose tissue that is capable of activating
A4 to T (22). The enzyme 5a-reductase type 1 (SRD5A1)
activates T in peripheral target tissues to the most potent
androgen, DHT, and is highly expressed in adipose tissue
(24). Studies in rodent and nonhuman primate models
show that pre- and postnatal androgen exposure in
women leads to increased adipocyte size, enlarged vis-
ceral fat depots, and reduced insulin sensitivity (25–27).
However, human data on the effects of AE on key pro-
cesses of adipose biology, such as adipogenesis and lipid
metabolism, are lacking.
In this study, we explored the hypothesis that increased
intra-adipose androgen generation by AKR1C3 is a central
driver of adipose tissue dysfunction and lipotoxicity in
PCOS. To test our hypothesis, we undertook a study using
innovative in vivo physiology tools for deep metabolic
phenotyping in a cohort of women with PCOS and age-,
sex-, and body mass index (BMI)–matched healthy con-
trols, alongside in vitro experiments defining the impact of
androgens on human adipocyte biology.
Methods
Study participants
Women with PCOS aged between 18 and 40 years were
recruited from outpatient clinics at University Hospitals Bir-
mingham and Birmingham Women’s Hospital. Full ethical ap-
proval was obtained from Edgbaston Research Ethics Committee
(reference no. 12/WM/0206) and all participants providedwritten
informed consent prior to inclusion in the study. PCOS was di-
agnosed according to the Rotterdam European Society of Human
Reproduction and Embryology 2004 criteria, with the presence of
two or more of the following: oligo/anovulation (Anov), clinical
signs of AE, and polycystic ovaries (PCOs) on ultrasound (10);
however, only PCOS women with clinical or biochemical signs of
AE were recruited to the in vivo study (phenotypes AE + Anov +
PCO, AE + Anov, and AE + PCO). Other potential causes of
oligomenorrhea and AE were excluded by history, physical ex-
amination, and biochemical assessment. All healthy controls were
age- and BMI-matched, and recruited via local advertisement,
with exclusion of PCOS on clinical and biochemical grounds.
Recruitment numbers for each study group were agreed based on
a priori power calculations; based on estimated detectable dif-
ferences and standarddeviations in adiposemicrodialysis data and
serum androgen profiles across the dehydroepiandrosterone
(DHEA) challenge, a sample size of 10 PCOS and 10 control
patients was deemed sufficient to achieve 80% statistical power
for the detection of a difference with P, 0.05. Exclusion criteria
for the study were as follows: recent glucocorticoid treatment
(within 3 months), pregnancy, age,18 or.45 years, recent oral
contraceptive use (within 3 months), hyperprolactinemia, thyroid
disorders, and dysglycemia (impaired fasting glucose, impaired
glucose tolerance, or overt diabetes mellitus). PCOS women
were also excluded if they had received prior treatment with
metformin, insulin sensitizers, or androgen receptor blockers.
Detailed information on the clinical protocol is provided in the
Supplemental Methods and Fig. 1(a). Subcutaneous abdominal
fat samples were obtained by excisional biopsy (2 to 3 cm3, ~3 to
5 g) in both PCOS and control women under local anesthetic
and sterile conditions, 5 cm lateral to the umbilicus. Excised
adipose tissue was immediately placed in RNALater (Life
Technologies, Paisley, United Kingdom) and stored at 220°C
for subsequent RNA extraction.
Biochemical analysis
Insulin (Mercodia, Uppsala, Sweden) and serum-free fatty
acids (Zen-Bio, Research Triangle Park, NC) were measured using
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commercially available assays, according to manufacturer in-
structions. Plasma glucose was measured using the 2300 STAT
PLUSanalyzer (YSI Inc., Life Sciences, OH).Homeostasismodel
assessment of insulin resistance (HOMA-IR) was calculated
using the formula [fasting glucose (mmol/L) 3 fasting insulin
(pmol/L)/135]. Microdialysate samples were collected in micro-
vials and analyzed using a mobile photometric, enzyme-kinetic
analyzer (CMA Iscus Flex;MDialysis AB, Johannesov, Sweden)
for glucose, pyruvate, lactate, and glycerol.
Steroid metabolite analysis (adipose microdialysate,
serum, and cellular supernatant)
Androgens from adipose microdialysate, serum, and cellular
supernatant were measured by liquid chromatography/tandem
mass spectrometry (LC-MS/MS) using an Xevo mass spec-
trometer with Acquity uPLC system (Waters, Herts, United
Kingdom), as described previously (11). Measurement of T,
A4, and DHEA was facilitated by serum steroid oxime
analysis, and carried out in positive mode. T, A4, and DHEA
were extracted from 150 mL interstitial fluid, 400 mL serum,
and 1 mL cellular supernatant via liquid-liquid extraction
with 1, 2, and 4 mL tert-butyl-methyl-ether, respectively. This
was followed by derivatization into oximes. Serum dehy-
droepiandrosterone sulfate was extracted from 20 mL serum
with 100 mL acetonitrile, before evaporation under constant
nitrogen flow (28).
For each LC-MS/MS assay, chromatography was opti-
mized using a methanol/water (0.1% formic acid) gradient
system. Steroids were quantified according to a linear cali-
bration series with appropriate internal standards. Individual
steroids were identified by matching retention times and two
mass transitions in comparison with a deuterated reference
compound.
Figure 1. Circulating androgens and in vivo intra-adipose tissue androgen synthesis in PCOS (n = 10) and age- and BMI-matched healthy
controls (n = 10). (a) Deep metabolic in vivo phenotyping protocol with serum and adipose microdialysate sampling every 30 minutes for 4 hours.
After baseline sampling, an acute androgen challenge was administered by oral intake of a 100-mg dose of the androgen precursor DHEA at
0 minutes; schematic represents the classic androgen synthesis pathway from DHEA to active androgens. (b–e) Serum and in vivo intra-adipose
concentrations of DHEA, A4, T, and 5a-DHT in controls (s) and PCOS women (C). Lines represent the median of each group. (f and g)
Steroid ratios reflective of the conversion of A4 to T (T:A4) and the conversion of T to DHT (DHT:T) as measured in serum and adipose tissue
microdialysate of PCOS women. Black squares represent PCOS serum. Lines represent the median of each group. (h and i) Relative messenger
RNA expression of the androgen-generating enzymes AKR1C3 (converting A4 to T) and SRD5A1 (converting T to DHT) in subcutaneous
abdominal adipose tissue from PCOS and controls (n = 7 for each). Lines represent the median of each group. (j and k) Serum T sulfate and DHT
glucuronide concentrations before and 150 minutes after oral administration of the androgen precursor DHEA. Boxes represent median and 25th
to 75th percentile, and whiskers represent 10th and 90th percentile. Significance levels: *P , 0.05; **P , 0.01; ***P , 0.001; ****P , 0.0001
(Mann-Whitney U test). All steroid concentrations were measured by mass spectrometry–based assays. mRNA, messenger RNA.
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Measurement of urinary steroid metabolite excretion by gas
chromatography mass spectrometry is described in the Sup-
plemental Methods.
Nontargeted serum metabolomics
We carried out mass spectrometry–based, nontargeted
metabolome analysis in negative and positive ion modes at
the Phenome Centre Birmingham, United Kingdom. In-depth
methodology for nontargeted serum metabolomic profiling has
been published by our group previously (24), and the full
protocol is available in the Supplemental Methods.
Primary human adipocyte culture
Paired primary subcutaneous preadipocytes were isolated
from adipose tissue obtained from healthy, nondiabetic women
aged 18 to 45 years undergoing elective abdominal laparoto-
mies for nonmalignant, noninflammatory disease, using
methods described previously (29). Samples from women with
diabetes or treated with systemic glucocorticoids in the last
3 months were excluded. Sample collection was facilitated via
the University of Birmingham Tissue Biorepository. Briefly,
adipose tissue samples were dissected into 2- to 3-mm3 pieces
and digested with type II collagenase (Sigma Aldrich, Dorset,
United Kingdom) at 37°C for 60 minutes. Samples were then
centrifuged at 12,000 rpm for 5 minutes. Preadipocytes were
extracted from a pellet containing the stromovascular
components and resuspended in Dulbecco’s modified Eagle
medium/nutrient mixture F12, containing fetal bovine se-
rum 10% (Sigma-Aldrich) and penicillin-streptomycin 1%
(ThermoFisher Scientific, Warrington, United Kingdom). Pre-
adipocytes were proliferated to confluence before chemically
defined culture media was applied for 14 days to stimulate
differentiation into adipocytes. Differentiation was initiated by
washing the cells in serum-free media, followed by culture with
differentiation media (Dulbecco’s modified Eagle medium–F12
media containing biotin 33 mM, pantothenate 17 mM, tri-
iodothyronine 1 nM, insulin 167 nM, cortisol 1 mM, and
rosiglitazone 1 mM). AKR1C3 activity was determined by
generation of T after incubation of cells with 200 nM of the T
precursor A4 in serum-free media for 24 hours.
Simpson-Golabi-Behmel syndrome preadipocyte cell
line culture
Conditions for culture and differentiation of the human
preadipocyte Simpson-Golabi-Behmel syndrome (SGBS) cell
line are described in the Supplemental Appendix.
Functional studies of lipid metabolism
A detailed description of methodology for de novo lipo-
genesis, b oxidation, and free fatty acid uptake is provided in the
Supplemental Appendix.
Statistics
SPSS version 22 (SPSS, Chicago, IL) was used for data
analysis. Data are presented as mean 6 standard error of the
mean unless otherwise stated. Baseline clinical and biochemical
data were not normally distributed and are therefore presented
as median and interquartile range. Area under the curve (AUC)
analysis was carried out using the trapezoidal method. For
comparison of single variables, t tests (paired or unpaired as
appropriate) were used, or nonparametric equivalents where
data were not normally distributed. One-way analysis of var-
iance with post hoc Tukey testing was used for multiple com-
parisons between different groups. For real-time polymerase
chain reaction data, statistical analysis was performed on mean
Dct values only. Correlation testing was performed using
Pearson correlation coefficient or Spearman test as appropriate.
Serummetabolomics data were analyzed by applying univariate
(Mann-Whitney U test or Wilcoxon signed-rank test) analysis
after normalization to total peak area per sample.
Results
Systemic androgen concentrations and measures of
insulin resistance
Ten womenwith PCOS and 10 healthy, sex-, age-, and
BMI-matched volunteers were recruited to an in vivo
physiology study for deep metabolic phenotyping [see
Fig. 1(a) and for detailed protocol description the Sup-
plemental Appendix]; clinical and biochemical charac-
teristics of both groups are summarized in Supplemental
Table 1.
Baseline circulating androgens, measured by LC-MS/
MS, were all significantly higher in PCOS than in con-
trols, as was insulin resistance assessed by HOMA-IR
(P = 0.003) (Supplemental Table 1). Similarly, truncal fat
mass and volume on body composition imaging by dual
x-ray absorptiometry were increased in the PCOS group
comparedwithmatched controls (Supplemental Table 1).
These findings demonstrate the expected systemic AE,
insulin resistance, and increased visceral adiposity in
PCOS subjects in comparison with sex-, age-, and BMI-
matched controls.
Adipose tissue-specific AE in PCOS
To explore in vivo androgen concentrations in the
adipose tissue metabolic compartment, we inserted a
microdialysis catheter into the abdominal subcutaneous
adipose tissue of each participant, which allowed the
sampling of adipose tissue interstitial fluid across a
semipermeable membrane. We used LC-MS/MS to
measure androgens in adipose microdialysate in both
PCOS and control subjects, representative of in vivo
intratissue androgen homeostasis.
Adipose tissue concentrations of the androgen pre-
cursors DHEA (P = 0.01) andA4 (P = 0.01) and the active
androgen T (P = 0.0006) were significantly increased in
PCOS subjects [Fig. 1(b–d)]. The most potent androgen
DHTwas quantifiable in adipose interstitial fluid in all 10
PCOS patients and in six of the 10 control patients, with
significantly higher concentrations in PCOS (4.56 1.7 vs
0.9 6 0.3 nmol/L, P = 0.01) [Fig. 1(e)]. Adipose tissue
microdialysate concentrations of DHEA, A4, and DHT all
correlated positively with HOMA-IR (R = 0.51, P = 0.02,
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R = 0.54, P = 0.01 and R = 0.44, P = 0.04, respectively),
whereas intra-adipose T correlated positively with fasting
insulin levels (R = 0.49, P = 0.04) (for complete correlation
analysis, see Supplemental Table 2).
Of note, concentrations of the androgen precursors
DHEA and A4 were higher in serum (i.e., in systemic
circulation) than in adipose tissue in both PCOS and
control women [Fig. 1(b) and 1(c)]. By contrast, intra-
adipose concentrations of the androgen receptor-
activating androgens T and DHT were significantly
higher than serum levels in PCOS women (P , 0.0001)
[Fig. 1(d) and 1(e)]. Androgen concentrations in control
women did not differ between circulation and adipose
tissue.
The intra-adipose ratio of T to A4, reflective of
AKR1C3 activity, was significantly higher than in serum
(P , 0.0001) [Fig. 1(f)] in the PCOS patients but not in
the BMI-matched controls (data not shown). Similarly, in
the PCOS women, the intra-adipose ratio of DHT to T,
reflecting 5a-reductase activity, was significantly higher
than in serum (P , 0.0001) [Fig. 1(g)].
Subcutaneous adipose tissue biopsies from PCOS and
control womenwere used for messenger RNA expression
analysis by real-time quantitative polymerase chain re-
action. This showed significantly increased AKR1C3
messenger RNA expression in subcutaneous fat from
PCOS women (mean Dct, 12.1 6 0.2 in PCOS vs 13.16
0.4 in controls, P = 0.04) [Fig. 1(h)]. Conversely, we
found significantly decreased intra-adipose expression of
SRD5A1 in PCOS women (mean Dct, 16.1 6 0.4 in
PCOS vs 14.3 6 0.4 in controls, P = 0.005) [Fig. 1(i)],
indicating that AKR1C3 is the major driver of intra-
adipose AE in PCOS.
Acute oral androgen challenge suppresses in vivo
lipolysis in PCOS adipose tissue
To examine the effect of androgens on in vivo adi-
pose tissue metabolism, study participants received an
oral dose of the androgen precursor DHEA at base-
line, followed by sampling of serum and adipose tissue
microdialysate every 30 minutes for 4 hours. We have
previously shown that this DHEA challenge test results in
rapid generation of downstream androgens that can be
detected in serum and urine (15, 30). After the oral in-
gestion of 100 mg DHEA, we measured circulating an-
drogens by LC-MS/MS and documented significantly
higher AUCs (mean6 standard error of the mean, nmol/
L$min) in women with PCOS for serum DHEA (7437 6
720 vs 43176 654 in controls, P = 0.005), A4 (2586 65
vs 63 6 25 in controls, P = 0.01), and T (2507 6 237 vs
1556 6 303 in controls, P = 0.01). Increased circulating
concentrations of T sulfate and DHT glucuronide after
DHEA exposure in both controls and PCOS (all P ,
0.0001) [Fig. 1(j) and 1(k)] further documented the extent
of acute androgen generation after DHEA administra-
tion. This demonstrates that we exposed both groups to
an equivalent acute androgen challenge on the back-
ground of chronic AE (PCOS) or normal circulating
androgen concentrations (controls).
To examine the in vivo metabolic impact of this an-
drogen load, we measured markers of insulin sensitivity
and lipid metabolism at baseline and after acute DHEA
exposure, looking at both systemic (serum) and tissue-
specific (adiposemicrodialysate) outcomes (Fig. 2). Plasma
glucose levels were similar at baseline and across the
DHEA challenge in both PCOS and controls [Fig. 2(a)].
Baseline fasting insulin was significantly increased in
PCOS (Supplemental Table 1), but AUC values for insulin
across the DHEA challenge (pmol/L$min) did not differ
significantly between PCOS and controls (14,672 6
4120 vs 80436 2958, P = 0.21) [Fig. 2(b)]. There was no
difference in baseline or AUC values for serum-free fatty
acids between the two groups [Fig. 2(c)].
Assessing the adipose tissue-specific in vivo metabolic
response, we measured metabolic markers in adipose
microdialysate. Adipose pyruvate, lactate, and glu-
cose did not differ significantly between PCOS women
and controls at baseline and in response to DHEA
[Fig. 2(d–f)]. However, AUC values for glycerol
(mM$min) significantly decreased in PCOS patients after
DHEA (35,347 6 4781 in PCOS vs 22,310 6 3577 in
controls, P = 0.04) [Fig. 2(g) and 2(h)], consistent with
decreased lipidmobilization in PCOS in response to acute
androgen exposure.
AE induces distinct changes in the circulating
metabolome in PCOS
Mass spectrometry–based nontargeted metabolome
analysis was used to determine differences in global
metabolic phenotype in PCOS serum compared with
controls before and after DHEA administration. At
baseline, we identified 119 metabolites that were statis-
tically different (P , 0.01) when comparing PCOS with
control subjects. Significantly perturbed metabolite
classes in PCOS included diacylglycerides, fatty acids
and oxidized fatty acids, sterol and steroid metabo-
lites, and glycerophospholipids (GPLs) and lysoglycer-
ophospholipids (LGPLs) [Fig. 3(a) and 3(b)]; other classes
included aromatic amino acid metabolism, ceramides
and sphingolipids, and ubiquinone/quinone metabolism.
Both oxidized and nonoxidized fatty acids and most
diacylglycerides showed higher concentrations in control
subjects, whereas GPL and LGPL concentrations were
higher in PCOS subjects.
In response to DHEA administration (i.e., acute an-
drogen exposure), the metabolome of PCOS patients
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(with a background of chronic AE) and that of BMI-
matched controls (with normal baseline androgens)
showed distinct changes [Fig. 3(c–f); Supplemental Ta-
ble 3]. DHEA induced highly substantial changes in 15
diacylglycerides, 32 fatty acids, and 16 oxidized fatty
acids in the control group; in PCOSwomen, changes were
observed in 16 diacylglycerides, 31 fatty acids, and 19
oxidized fatty acids. In all cases, DHEA reduced circu-
lating concentrations of diacylglycerides and oxidized
and nonoxidized fatty acids compared with baseline, in
both PCOS and controls, a demonstration of the potent
effects of androgens in the regulation of lipid metabolism.
Of note, most GPLs and LGPLs, which were signifi-
cantly increased in PCOS at baseline [Fig. 3(b)], showed a
diametrically opposed metabolic response to the acute
androgen challenge, with substantial further upregula-
tion in PCOS and downregulation in the BMI-matched
healthy controls [Fig. 3(e) and 3(f); Supplemental Ta-
ble 3], indicating a distinctly different metabolic response
to androgens in PCOS.
Androgens promote adipose lipid accumulation
in vitro
To dissect the observed effects in further detail, we
used a human preadipocyte cell line, SGBS, previously
validated as a model of human subcutaneous adipocyte
biology (31). To determine the role of androgens in
adipose lipid metabolism, differentiated adipocytes were
treated with increasing concentration of T and DHT.
Androgen treatment of 24 hours resulted in a dose-
dependent increase in messenger RNA expression of
acetyl-CoA-carboxylase (ACC) 1, the rate-limiting step in
lipogenesis, but not ACC2 (fold change vs untreated
control: T 20 nM, 1.3 6 0.1; P = 0.02; T 40 nM, 1.6 6
0.1; P, 0.001; DHT 10 nM, 1.86 0.3; P = 0.006; DHT
20 nM, 2.2 6 0.8; P = 0.01) [Fig. 4(a)].
Consistent with upregulation of ACC1 messenger
RNA expression, T 40 nM significantly increased de
novo lipogenesis in SGBS cells in the absence of insulin, as
measured by uptake of 1-[14C]-acetate incorporation into
lipid (150.4% 6 7.3% of untreated cells, P = 0.02)
[Fig. 4(b)]. This effect was also observed with DHT 20
nM (121.9% 6 8.4% of untreated cells, P = 0.03),
confirming it as androgen-mediated as DHT, in contrast
with T, cannot be converted to estrogens via aromatase
activity. Insulin (5 nM) expectedly resulted in a signifi-
cant increase of de novo lipogenesis compared with
control incubations without insulin (250.0% 6 19.1%,
P = 0.009). However, there was no additional effect of
insulin when added to the incubations with androgens
(P = 0.9 for both T and DHT).
In SGBS cells, exposure to DHT 20 nM significantly
decreased b oxidation of fatty acids compared with
untreated control cells (83.2% 6 5.9%, P = 0.03)
[Fig. 4(c)], whereas we did not observe androgen effects
on free fatty acid uptake [Fig. 4(d)].
AKR1C3 links adipose AE and lipid accumulation
in PCOS
To examine the role of insulin in AKR1C3-mediated
androgen generation, we examined expression and ac-
tivity of AKR1C3 in primary human adipocytes and
SGBS cells before and after insulin treatment. AKR1C3
messenger RNA expression increased significantly across
Figure 2. Impact of acute oral androgen challenge (DHEA 100 mg) on in vivo metabolic markers in serum and adipose tissue microdialysate.
Serum glucose, insulin, and free fatty acids (a–c) and intra-adipose pyruvate, glucose, lactate, and glycerol levels (d–g) in PCOS (n = 10, dark line,
C) and control women (n = 10, dotted line, s across the DHEA challenge test) (mean 6 standard error of the mean). Time of oral
administration of 100 mg DHEA indicated by arrow. (h) AUC for glycerol between 120 and 240 minutes after androgen exposure in the PCOS
group compared with controls. *P , 0.05 (Mann-Whitney U test). For further details see Supplemental Methods.
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Figure 3. Baseline differences and changes induced in the nontargeted serum metabolome by acute androgen exposure in women with PCOS
(n = 10) and age- and BMI-matched healthy control women (n = 10). (a) The number of serum metabolites associated with lipid and steroid
metabolism observed to be significantly different (P , 0.01) at baseline between control and PCOS subjects. (b) Significantly different GPL and
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differentiation from preadipocyte (day 0) to the mature
adipocyte (day 14) phenotype in both subcutaneous and
omental female adipocytes (mean Dct for subcutaneous
fat, 16.4 6 0.5 for preadipocytes vs 11.7 6 1.3 for ad-
ipocytes; P = 0.03; mean Dct for omental fat, 19.5 6 0.1
for preadipocytes vs 11.4 6 1.1 for adipocytes; P =
0.001). AKR1C3 activity, as determined by generation of
T after incubation of cells with 200 nM A4 for 24 hours,
was significantly upregulated across adipocyte differen-
tiation in both subcutaneous and omental fat depots
(P = 0.02 and P = 0.04, respectively).
AKR1C3 messenger RNA expression increased sig-
nificantly in both SGBS and primary female subcutane-
ous adipocytes (n = 3) after exposure to insulin 20 nM
(P = 0.03 and P = 0.04, respectively) [Fig. 5(a) and 5(c)],
but not in primary female omental adipocytes (n = 3,
P = 0.18). Similarly, AKR1C3 activity was significantly
increased by insulin exposure at doses in SGBS cells and
primary female subcutaneous adipocytes [Fig. 5(b) and
5(d)], but not in primary omental adipocytes.
Selective pharmacologic AKR1C3 inhibition with 3-4-
trifluoromethyl-phenylamino-benzoic acid (10 mM for
Figure 4. The effects of androgens on adipose lipid metabolism in the human preadipocyte SGBS cell line. (a) The effect of androgens (T, light-
shaded bars; 5a-DHT, dark-shaded bars) on the messenger RNA expression of ACC1, the main provider of malonyl-CoA for fatty acid synthesis.
(b) Effect of T and DHT on de novo lipogenesis, determined by incorporation of 14C acetate into lipid. (c) Effects of T and DHT on b oxidation,
determined by 3H20 release from
3H-palmitate. (d) Effects of androgens on free fatty acid uptake. All data are presented as the mean 6 standard
error of the mean of the three to five experiments. Significance levels: *P , 0.05; **P , 0.01; ***P , 0.001 compared with control (analysis of
variance with post hoc Tukey test). mRNA, messenger RNA.
Figure 3. (Continued). LGPL metabolites between PCOS women and controls at baseline. (c and d) Metabolic responses lipid and steroid
metabolite after exposure of controls and PCOS subjects to an acute androgen challenge (DHEA 100 mg administered orally at 0 minutes; serum
metabolome analysis carried out with 150-minute serum sample, representative of the maximum of circulating androgen concentrations after
DHEA). (e and f) Differential response of GPLs and LGPLs to the acute DHEA challenge in comparison of controls and PCOS women. Data matrix
analyzed applying univariate (Wilcoxon signed-rank test) after normalization to total ion current per sample. DAG, diacylglyceride; FA, fatty acid;
OFA, oxidized fatty acids; SS, sterols and steroid metabolites.
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Figure 5. Expression, activity, and inhibition of the androgen-activating enzyme AKR1C3 in subcutaneous adipose tissue. (a–d) Expression and
activity of AKR1C3 with and without insulin stimulation in the human preadipocyte SGBS cell line and primary subcutaneous adipocytes from
women undergoing elective surgery. (e) Effect of pharmacologic AKR1C3 inhibition by 3-4-trifluoromethyl-phenylamino-benzoic acid (10 mM) for
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24 hours) significantly reduced generation of active an-
drogen T from the androgen precursor A4. This was
observed in both control adipocytes and those treated
with 10 nM insulin (100% for control vs 59%6 3% for
inhibitor, P , 0.0001; 131% 6 10% for 10 nM insulin
vs 77% 6 16% for inhibitor, P = 0.02) [Fig. 5(e)]. Ad-
ipocytes treated with 100 nM A4 showed significantly
increased de novo lipogenesis (179.4% 6 21.5%, P =
0.002); this effect was significantly attenuated by coin-
cubation with the selective AKR1C3 inhibitor (P = 0.04)
[Fig. 5(f)]. Hence, disruption of AKR1C3-mediated
androgen generation ameliorates androgen-mediated
adverse effects on adipocyte lipogenesis, thereby mech-
anistically linking AE and insulin resistance.
Discussion
Using a human in vivo physiology approach, we have
demonstrated an adipose tissue-driven mechanistic link
between AE and lipid metabolism in PCOS. We used
mass spectrometry to determine both systemic and adi-
pose tissue androgen concentrations, revealing signifi-
cantly increased androgen synthesis in PCOS adipose
tissue, alongside increased expression and activity of
the androgen-activating enzyme AKR1C3. This demon-
strates the important capacity of adipose tissue to act as a
source of AE in PCOS. Furthermore, androgens promoted
in vitro lipid accumulation in human adipocytes, and
suppressed in vivo lipolysis in women with PCOS. The net
effect of this is promotion of adipocyte hypertrophy.
Enlarged, lipid-overloaded adipocytes are insulin resistant
(32), fueling the adverse metabolic phenotype observed in
PCOS, with lipid overspill and lipotoxicity in other organs
such as the liver. We could show that in vitro inhibition of
AKR1C3 decreased AE and subsequently de novo lipo-
genesis, identifying AKR1C3 as a target for therapeutic
intervention in PCOS.
Several 17b-hydroxysteroid dehydrogenase enzymes
are capable of activating A4 to T, but of those, only
AKR1C3 is expressed in human adipose tissue (22). In-
terestingly, expression of the androgen-inactivating en-
zyme HSD17B2, which is capable of inactivating T to A4
and has been detected in omental adipose tissue (33), was
not detectable in subcutaneous adipose tissue in this study
or in previous work by our group (22). Our studies reveal
the androgen-activating enzyme AKR1C3 as the pre-
dominant driver of active androgen generation in adipose
tissue of PCOS patients. AKR1C3 is a crucial enzyme in
androgen biosynthesis in the adrenal, ovary, prostate,
and adipose tissue (34), and AKR1C3 single nucleotide
polymorphisms have been reported as associated with an
increased prevalence of PCOS and hyperandrogenism in
women (35). BMI differed slightly between the control and
PCOS groups in this study (median, 33.1 vs 28.6 kg/m2);
however, this difference did not show statistical signifi-
cance, possibly because of the size of the cohorts. With
this minor caveat in mind, our finding of increased
AKR1C3 expression and activity confirm and expand the
significance of results from a previous study describing
increased AKR1C3 messenger RNA expression in sub-
cutaneous adipose tissue of PCOS women (23).
In our in vitro studies, we conclusively demonstrated
that AKR1C3 expression is regulated by insulin, mech-
anistically linking AE and insulin resistance, the two
major metabolic features in PCOS.We found that insulin
increased AKR1C3 expression and T generation in vitro,
and in vivo we found a significant correlation between
adipose tissue T and circulating insulin. Some previously
published evidence had provided preliminary evidence
for the potential regulation of adipose androgen meta-
bolism by insulin. The fasting-induced transcription
factor Kruppel-like factor 15 (KLF15) is crucially re-
quired for adipocyte differentiation (36), represents a key
regulator of gluconeogenesis (37), and has been recently
shown to represent a molecular link between glucose
metabolism and lipogenesis (38). The AKR1C3 promoter
contains a KLF15 binding site, and in vitro over-
expression of KLF15 results in increased AKR1C3 pro-
moter activity and T formation by adrenal NCIH295R
cells (39). Intriguingly, we found increased expression of
both AKR1C3 and KLF15 in the subcutaneous adipose
tissue biopsies in our PCOS patients.
In this study, we demonstrated the functional impact
of chronic and acute androgen exposure on the regulation
of adipose tissue lipid metabolism, demonstrating sup-
pressed lipolysis in vivo and increased lipogenesis in vitro.
Data from nontargeted serum metabolomics support this
observation of enhanced lipogenesis in PCOS. Serum
metabolomics also revealed significantly increased con-
centrations of GPLs and LGPLs inwomenwith PCOS but
not in controls; the acute androgen challenge yielded a
further increase of these metabolites in PCOS patients,
whereas concentrations in BMI-matched controls de-
creased. This demonstrates distinctly different metabolic
responses to androgens in PCOS and controls and sug-
gests that AE plays a distinct role in creating a lipotoxic
metabolic environment. Both GPLs and LGPLs pre-
viously identified as markers of risk and progression in
Figure 5. (Continued). 24 hours (gray bars) on adipose androgen generation, assessed as conversion of A4 to testosterone. (f) Impact of
pharmacologic AKR1C3 inhibition on A4-mediated de novo lipogenesis. All data are presented as the mean 6 standard error of the mean of 3 to
5 experiments. Significance levels: *P , 0.05; **P , 0.01; ***P , 0.001 (analysis of variance with Tukey post hoc test).
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nonalcoholic fatty liver disease (40), which is more
prevalent in women with PCOS.
In conclusion, we have shown evidence that intra-
adipose AE and dysfunctional adipose lipid metabolism
are causally linked drivers of adverse metabolic risk in
PCOS. We have described putative mechanisms by
which androgens regulate adipose tissue function, lipid
metabolism, and fat mass and have highlighted, at the
level of the adipocyte, the enzyme AKR1C3 as a key
regulator linking insulin resistance and AE in PCOS.We
postulate that a vicious circle in adipose tissue drives
metabolic risk in PCOS [Fig. 6(a)], consisting of in-
creased androgen generation in adipose tissue byAKR1C3,
subsequent lipid accumulation, and increased fat mass,
resulting in systemic insulin resistance and lipotoxic organ
damage, with androgen generation further exacerbated by
hyperinsulinemia. We have shown that selective in vitro
inhibition of AKR1C3 significantly reduced androgen-
induced de novo lipogenesis. This suggests that local
generation of T from A in subcutaneous adipose tissue by
AKR1C3 is an important driver of androgen-mediated
lipid accumulation.
The disruption of this vicious circle should now be
studied in patients with PCOS, using selective pharma-
cologic inhibition of AKR1C3. Murine models are not
suitable for the exploration of human androgen synthesis
and metabolism as steroidogenic enzymes such as the
17b-hydroxysteroid dehydrogenase family are very dif-
ferently organized in mice and humans. In humans,
AKR1C3 is a central gatekeeper enzyme not only in
classic androgen synthesis, but also in the alternative
pathway to DHT synthesis (41) and the 11-oxygenated
Figure 6. (a) Schematic representation of the proposed mechanistic link between AE, insulin resistance, and lipotoxicity in PCOS, and (b)
graphical representation of the major human androgen biosynthesis pathways. AKR1C3 plays a central gatekeeping role in androgen activation in
the classic androgen synthesis pathway and the alternative (backdoor) pathway to 5a-DHT and the 11-oxygenated androgen synthesis pathway.
Active androgens capable of activating the androgen receptor highlighted in blue boxes and white font.
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androgen pathway (42). Recent work (43) has shown
that 11-oxygenated androgens represent most circulating
androgens in PCOS, including 11-keto-T, which has
three- to fourfold higher serum concentrations than T in
PCOS patients, while activating the androgen receptor
with similar potency. Therefore, selective AKR1C3 in-
hibition is likely to provide the most efficient control of
PCOS-related AE [Fig. 6(b)]. In addition, based on our
findings, inhibition of AKR1C3 is likely to exert bene-
ficial effects on the adverse metabolic phenotype in
PCOS, through amelioration of both circulating andro-
gen burden and abnormal adipose tissue biology.
In conclusion, AKR1C3 represents a highly promising
therapeutic target in women with PCOS.
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